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Success Rate and Risk Factors for Failure of Empirical Antifungal 
Therapy with Itraconazole in Patients with Hematological 
Malignancies: A Multicenter, Prospective, Open-Label, 
Observational Study in Korea
We assessed the success rate of empirical antifungal therapy with itraconazole and 
evaluated risk factors for predicting the failure of empirical antifungal therapy. A 
multicenter, prospective, observational study was performed in patients with 
hematological malignancies who had neutropenic fever and received empirical antifungal 
therapy with itraconazole at 22 centers. A total of 391 patients who had abnormal findings 
on chest imaging tests (31.0%) or a positive result of enzyme immunoassay for serum 
galactomannan (17.6%) showed a 56.5% overall success rate. Positive galactomannan 
tests before the initiation of the empirical antifungal therapy (P = 0.026, hazard ratio [HR], 
2.28; 95% confidence interval [CI], 1.10-4.69) and abnormal findings on the chest 
imaging tests before initiation of the empirical antifungal therapy (P = 0.022, HR, 2.03; 
95% CI, 1.11-3.71) were significantly associated with poor outcomes for the empirical 
antifungal therapy. Eight patients (2.0%) had premature discontinuation of itraconazole 
therapy due to toxicity. It is suggested that positive galactomannan tests and abnormal 
findings on the chest imaging tests at the time of initiation of the empirical antifungal 
therapy are risk factors for predicting the failure of the empirical antifungal therapy with 
itraconazole. (Clinical Trial Registration on National Cancer Institute website, 
NCT01060462)
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INTRODUCTION
Most patients with hematological malignancies belong to the intermediate-to-high 
risk group of infection (1). Among the various causes of infection, invasive fungal dis-
ease (IFD) is one of the most important causes of morbidity and mortality (2). Europe-
an data report an overall incidence of 4.6% of IFD in patients with hematological ma-
lignancies (3). Therefore, early diagnosis and proper treatment of IFD is very impor-
tant. However, it is difficult to make a definitive diagnosis of proven IFD because most 
patients with suspected IFD are usually hemodynamically unstable and accompanied 
by advanced coagulation deficits (4, 5). To overcome these issues, the use of empirical 
antifungal therapy for suspected IFD has been established for neutropenic cancer pa-
tients with persistent fever, despite the use of broad-spectrum antibiotics (6-9); and 
appropriate empirical antifungal therapy is still a very important strategy in the man-
agement of patients with hematological malignancies (10). 
 Although deoxycholate amphotericin B (D-AMB) has been used in empirical anti-
fungal therapy, liposomal amphotericin B (L-AMB), itraconazole, voriconazole, or ca-
spofungin are commonly recommended for empirical antifungal therapy (11, 12). Be-
cause the efficacies of these antifungal agents as an empirical antifungal therapy were 
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similar (13-17), we could generalize the results of this study 
with itraconazole. The previous trials using itraconazole for em-
pirical antifungal therapy enrolled a relatively small number of 
patients and used different criteria of success for empirical an-
tifungal therapy (14, 18-20). Under such conditions, it was very 
difficult to compare the efficacy of itraconazole for empirical 
antifungal therapy with that of other antifungal agents. In addi-
tion, it is also difficult to evaluate risk factors for failure of em-
pirical antifungal therapy. 
 In this study, we assessed the success rate of empirical anti-
fungal therapy with itraconazole using 5 endpoints for success 
outcomes of empirical antifungal therapy (13, 15, 16) and also 
evaluated risk factors for failure of empirical antifungal therapy 
using these standardized results for success.  
 
MATERIALS AND METHODS
Study design 
This study was a multicenter, prospective, observational study 
conducted at 22 medical centers in Korea. Between July 2008 
and March 2009, 438 patients with hematological malignancies 
who had persistent or recurrent neutropenic fever had been 
enrolled. The primary objective of this study was to evaluate the 
overall success rate of empirical antifungal therapy with itra-
conazole. The secondary objective was to define the risk factors 
for failure of empirical antifungal therapy with itraconazole. To 
compare the effect of the time to initiation of empirical antifun-
gal therapy on the efficacy and safety of empirical antifungal 
therapy with itraconazole, we divided the patients into 2 groups 
(1-3 days vs ≥ 4 days after the onset of neutropenic fever) be-
cause empirical antifungal therapy is usually recommended 
when the fever does not resolve within 3-to-7 days of initial ad-
ministration of antibacterial agents (5, 8, 9). Efficacy was as-
sessed for the patients who received intravenous (IV) itracon-
azole for 3 or more days. Safety was assessed for all patients who 
received at least one dose of IV itraconazole. 
Patient eligibility
Patients 18 yr or older with persistent (more than 2 days) or re-
current neutropenic fever despite empirical broad-spectrum 
systemic antibacterial therapy (9) were eligible. Fever was de-
fined as a single oral temperature of above 38.3°C or a tempera-
ture of above 38.0°C for 1 hr (8, 9). Neutropenia was defined as 
an absolute neutrophil count (ANC) < 500/μL, or an ANC <  
1,000/μL with a predicted decrease to below 500/μL (8, 9). We 
started the granulocyte colony stimulating factor (G-CSF) ad-
ministration from the day of the ANC < 1,000/μL until recovery 
of ANC > 3,000/μL. The patients with possible or probable cat-
egories of IFD according to the European Organization for Re-
search and Treatment of Cancer/Mycoses Study Group (EOR-
TC/MSG) criteria were enrolled (4). Patients with a proven IFD 
were not eligible. However, we included patients with candidia-
sis. Other exclusion criteria were a history of hypersensitivity to 
itraconazole, a severe liver dysfunction (defined as a bilirubin 
level > 3 times the upper limit of normal [ULN] or an amino-
transferase/alkaline phosphatase level > 5 times the ULN) and 
severe renal dysfunction (defined as a calculated creatinine clear-
ance < 30 mL/min) (21). 
Treatment schedule and dose
IV itraconazole (Janssen Pharmaceutica, Beerse, Belgium) at a 
dose of 200 mg was administered every 12 hr for the first 2 days, 
followed by 200 mg once a day for the 14th day at maximum. 
After using IV itraconazole, an oral solution form of itraconazole 
at a dose of 200-400 mg/day replaced IV itraconazole when 
necessary. The patients with no evidence of baseline or break-
through fungal infections were recommended to continue em-
pirical antifungal therapy with IV itraconazole until deferves-
cence and recovery from neutropenia (ANC > 500/μL for at 
least 3 successive days). The patients who received a combina-
tion therapy with other antifungal agents were excluded. 
Analysis of efficacy and safety
The efficacy assessments for empirical antifungal therapy have 
been determined by 5 endpoints that have been used in previ-
ous studies (13, 15, 16). Treatment was considered successful if 
all 5 of the following criteria were met: 1) successful treatment 
of any baseline fungal infection, 2) the absence of any break-
through fungal infection, 3) survival for at least 7 days after dis-
continuation of itraconazole therapy, 4) resolution of fever (de-
fined as a temperature below 38°C for at least 2 days) during 
neutropenia, and 5) no premature discontinuation of the itra-
conazole therapy because of drug-related toxicity or lack of effi-
cacy.
 Baseline fungal infections were defined as those that devel-
oped within the first 48 hr after entry into the study (13, 15, 16). 
Breakthrough fungal infections were defined as those that oc-
curred from the 3rd day of treatment of IV itraconazole therapy 
or within 7 days after completion of itraconazole therapy (13, 
15, 16). The diagnosis of baseline or breakthrough fungal infec-
tion was confirmed when the patients were diagnosed as prov-
en or probable IFD according to the EORTC/MSG consensus 
criteria (4).
 The patients who received empirical IV itraconazole therapy 
between the 1st and 3rd day after initiation of antibacterial ther-
apy for neutropenic fever were defined as the “early administra-
tion” group. And the other patients who used empirical IV itra-
conazole therapy from the 4th day of antibacterial therapy were 
considered as the “routine administration” group.
 The safety assessments were performed according to the NCI 
Common Terminology Criteria for Adverse Effects, version 3.0 
(22). Clinical adverse events were monitored prospectively and 
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toxicities were defined as 2 or more grade toxicity and an incre-
ment of one or more grades above the baseline grade level. 
Statistical analysis
The defervescence rate prior to the recovery of ANC expected 
in this study was 40% ± 10% based on the results of previous 
studies (14, 20). The calculated number of patients was 369 based 
on a 95% confidence interval (CI) with estimated differences of 
10%. We also estimated a total sample size of 440 considering 
about a 15% drop-out rate. Categorical values were compared 
using a chi-square test or Fisher’s exact test. Continuous vari-
ables were compared using an independent sample t-test. All 
results were considered statistically significant at P < 0.05. Two-
sided 95% CIs were calculated where appropriate. The multi-
variate logistic regression analysis using identified significant 
factors in univariate analysis was performed. All calculations 
were performed with the SPSS system, version 18.0 (SPSS, Inc., 
Chicago, IL, USA).
Ethics statement 
This study was conducted according to the Declaration of Hel-
sinki and approved by institutional review board of Severance 
Hospital (IRB No. 4-2008-0232) and the institutional review 
boards of 21 other participating institutions. All subjected pa-
tients signed an informed consent. This study was registered on 
National Cancer Institute (NCI) website, NCT01060462.
RESULTS
Clinical characteristics
Among the 438 patients recruited, 9 were excluded because the 
patients did not receive IV itraconazole for 3 or more days while 
38 patients were excluded because of inappropriate inclusion/
exclusion criteria. A total of 391 patients was analyzed. The clin-
ical characteristics are summarized in Table 1. The median age 
was 50 yr (range, 18-78 yr). At the initiation of empirical anti-
fungal therapy, 291 patients (74.4%) had the status of residual 
hematological malignancies and 174 patients (44.5%) had a 
high score of Eastern Cooperative Oncology Group (ECOG) 
performance status (≥ 2). Co-morbidities were reported in 129 
patients (33.0%). There were no differences in these clinical char-
acteristics between the “early administration” group and the 
“routine administration” group (Table 1). 
 At the initiation of empirical antifungal therapy, 121 patients 
(31.0%) showed abnormalities (some evidence of infection) on 
chest X-rays or high-resolution computerized tomography (CT); 
and 23.2% of patients (22/95) had definite evidences of fungal 
infection on chest CT such as dense, well-circumscribed lesi-
ons(s) with or without a halo sign, air-crescent sign and cavity 
(4). Thirty-nine (17.6%) out of 221 patients had a positive result 
of enzyme immunoassay for serum galactomannan when us-
ing a cut-off index of 0.5 (23, 24). Among the 22 patients with 
definite evidences of fungal infection, 11 patients performed 
Table 1. Patient characteristics
Characteristics
Total patients 
(n = 391)
Early administration group 
(n = 276)
Routine administration group 
(n = 115)
P value
Age ≥ 60 yr old  114 (29.2)  84 (30.4)  30 (26.1) NS
Male: Female  1.3:1  1.3:1  1.6:1 NS
Underlying disease
Acute myeloid leukemia
Acute lymphoblastic leukemia
Myelodysplastic syndrome
Malignant lymphoma
Multiple myeloma
 223 (57.0)
 57 (14.6)
 28 (7.2)
 70 (17.9)
 13 (3.3)
 144 (52.2)
 42 (15.2)
 21 (7.6)
 58 (21.0)
 11 (4.0)
 79 (68.7)
 15 (13.0)
 7 (6.1)
 12 (10.4)
 2 (1.7)
NS
Disease status of underlying disease
Induction treatment
Salvage treatment/no treatment
Consolidation treatment
 163 (41.7)
 128 (32.7)
 100 (25.6)
 114 (41.3)
 93 (33.7)
 69 (25.0)
 49 (42.6)
 35 (30.4)
 31 (27.0)
NS
HSCT
Autologous HSCT
Allogeneic HSCT
 44 (11.3)
 28 (7.2)
 16 (4.1)
 33 (12.0)
 22 (8.0)
 11 (4.0)
 11 (9.6)
 6 (5.2)
 5 (4.3)
NS
ECOG performance status
0/1
2/3/4
40/177
143/25/6
32/127
91/21/5
 8/50
 52/4/1
NS
Co-morbidities
Cardiovascular disease
Diabetes Mellitus
Lung disease
Liver disease
Renal disease
Other serious medical conditions
 129 (33.0)
 66 (16.9)
 45 (11.5)
 23 (5.9)
 19 (4.9)
 9 (2.3)
 18 (4.6)
 92 (33.3)
 47 (17.0)
 31 (11.2)
 17 (6.2)
 12 (4.3)
 6 (2.2)
 15 (5.4)
 37 (32.2)
 19 (16.5)
 14 (12.2)
 6 (5.2)
 7 (6.1)
 3 (2.6)
 3 (2.6)
NS
Data are number (%) of patients, unless otherwise indicated. HSCT, hematopoietic stem cell transplantation; ECOG, Eastern Cooperative Oncology Group; NS, no significance. 
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serum galactomannan tests and 4 patients showed a positive 
galactomannan test. The median duration of baseline (prior to 
starting IV itraconazole) neutropenia (ANC < 500/μL) was 7 
days (interquartile range, 4-11). Prolonged baseline neutrope-
nia (> 10 days) was observed in 29.4% (n = 115) of the patients. 
The median duration of severe baseline neutropenia (ANC <  
100/μL) was 5 days (interquartile range, 2-9). Prolonged severe 
neutropenia ( > 10 days with ANC < 100/μL) was observed in 
61 patients (15.6%). Baseline duration of neutropenia was short-
er in the patients from the “early administration” group com-
pared with the “routine administration” group (Table 2). The 
median time to the start of empirical antifungal therapy with IV 
itraconazole after developing neutropenic fever was 2 days (ran-
ge, 1-18 days). 
 Approximately half of patients had received antifungal pro-
phylaxis (n = 190, 48.6%) and about half of them received a flu-
conazole as antifungal prophylaxis. The rate of prophylactic use 
of antifungal agents was lower in the patients in the “early ad-
ministration” group (43.1%) compared with the “routine ad-
ministration” group (61.7%) (P = 0.001, Table 2). Thirty patients 
(7.7%) had baseline fungal infections.
Efficacy analysis
The median treatment duration of IV itraconazole for empirical 
antifungal therapy was 9 days (range, 3-41 days). Forty-five pa-
tients (11.5%) switched from IV to the oral solution itraconazole. 
The overall success rate was 56.5% and there was no significant 
difference in the success rate between the two groups (Table 3). 
Of the 30 patients with baseline fungal infections, 15 patients 
(50.0%) had a successful outcome. Among 20 patients with in-
vasive aspergillosis as a baseline fungal infection, 10 patients 
had a successful outcome. The rate of breakthrough of fungal 
infections was 2.8% (11/391) and 9 of those patients were prob-
able or proven invasive aspergillosis. Other breakthrough fun-
Table 2. Baseline characteristics and risk factors for invasive fungal diseases 
Characteristics
Total patient 
(n = 391)
Early administration group 
(n = 276)
Routine administration group 
(n = 115)
P value
Positive serum galactomannan tests  39/221 (17.6)  26/147 (17.7)  13/74 (17.6)  NS
Abnormal findings on chest X-rays or CT  121 (31.0)  89 (32.4)  32 (27.8)  NS
Definite evidence of fungal infection  on CT  22 (5.6)  15 (5.4)  7 (6.1)  NS
Duration of baseline neutropenic fever, median (range) 2 (1-18) 1 (1-3) 5 (4-18) < 0.001
Duration of baseline neutropenia
> 6 days with ANC < 500/µL
> 10 days with ANC < 500/µL
> 4 days with ANC < 100/µL
> 10 days with ANC < 100/µL
 204 (52.2)
 115 (29.4)
 196 (50.1)
 61 (15.6)
 118 (42.8)
 62 (22.5)
 114 (41.3)
 34 (12.3)
 86 (74.8)
 53 (46.1)
 82 (71.3)
 27 (23.5)
< 0.001
< 0.001
< 0.001
     0.009
Antifungal prophylaxis
Nystatin
D-AMB
Fluconazole
Itraconazole
Voriconazole
Micafungin
 190 (48.6)
13
11
99
59
  1
  7
 119 (43.1)
10
  7
 60
 37
  0
  5
 71 (61.7)
  3
  4
39
22
  1
  2
     0.001
Baseline fungal infection
Candida
Aspergillus
Other species
 30 (7.7)
  5
20
  5
 20 (7.2)
  4
12
  4
10 (8.7)
1
8
1
 NS
Data are number (%) of patients, unless otherwise indicated. CT, computed tomography; ANC, absolute neutrophil count; D-AMB, deoxycholate amphotericin B; NS, no signifi-
cance.
Table 3. Outcomes of empirical antifungal therapy with itraconazole
Outcomes
Total patients 
(n = 391)
Early administration group 
(n = 276)
Routine administration group 
(n = 115)
P value
Overall success rate  221/391 (56.5)  152/276 (55.1)  69/115 (60.0) 0.433
Successful treatment of baseline fungal infection  15/30 (50.0)  11/20 (55.0)  4/10 (40.0) 0.700
Absence of breakthrough fungal infection  380/391 (97.2)  269/276 (97.5)  111/115 (96.5) 0.738
Survival for ≥ 7 days after completion of itraconazole  368/391 (94.1)  258/276 (93.5)  110/115 (95.7) 0.486
Resolution of fever in setting of neutropenia 
Time to defervescence during neutropenia, median days (range)
 232/391 (59.3)
 2 (range, 0-9)
 160/276 (58.0)
 2 (range, 0-9)
 72/115 (62.6)
 2 (range, 0-8)
0.430
0.167
Itraconazole discontinued prematurely because of toxicity or lack of efficacy
Yes
Lack of efficacy
Drug toxicity
 96/391 (24.6)
 88/391 (22.5)
 8/391 (2.0)
 66/276 (23.9)
 59/276 (21.4)
 7/276 (2.5)
 30/115 (26.1)
 29/115 (25.2)
 1/115 (0.9)
0.247
Data are number of patients with positive results/number of patients tested (%), unless otherwise indicated. 
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gal infections were candidiasis (n = 1) and coccidioidomycosis 
(n = 1). The proportion of patients who survived for at least 7 
days after completion of itraconazole therapy was 94.1% and 
the rate of resolution of fever during the neutropenic period 
was 59.3%. Premature discontinuation of itraconazole therapy 
because of toxicity or lack of efficacy occurred in 96 patients 
(24.6%). After failure of empirical antifungal therapy with itra-
conazole, 76 patients (19.4%) received second-line IV antifun-
gal therapies with D-AMB (n = 71), L-AMB (n = 2), caspofungin 
(n = 1), fluconazole (n = 1), or voriconazole (n = 1). The success 
rate was significantly lower in the patients with positive galac-
tomannan test and/or definite evidences of fungal infection on 
imaging study (pre-emptive therapy, 42.1%, 24/57) than the pa-
tients with negative galactomannan test and no evidences of 
fungal infection (58.9%, 103/175, P = 0.032) 
Safety and toxicity
Adverse events that might be related to itraconazole developed 
in 79 patients (18.0%). Hepatotoxicity (n = 68, 15.5%) and neph-
rotoxicity (n = 11, 2.5%) were commonly observed. Three pa-
tients experienced a generalized skin rash. Eight patients (2.0%) 
had premature discontinuation of itraconazole therapy due to 
toxicity. The causes of withdrawal from itraconazole therapy 
were hepatotoxicity (n = 6), nephrotoxicity (n = 2) and skin tox-
icity (n = 1).
Clinical characteristics and success rate of empirical 
antifungal therapy
There were no significant differences in success rates according 
to the underlying hematological malignancies (Table 4). The 
patients with cardiovascular co-morbidity were relatively less 
likely to achieve a successful outcome with empirical antifungal 
therapy (P = 0.056). Abnormal findings on chest X-rays or CT 
and positive galactomannan tests before initiation of empirical 
antifungal therapy were significantly associated with decreased 
success rates (P = 0.006, P = 0.033, respectively). 
 Multivariate analysis revealed that positive galactomannan 
tests before initiation of empirical antifungal therapy (P = 0.026, 
hazard ratio [HR], 2.28; 95% CI, 1.10-4.69) and abnormal find-
ings on chest X-rays or CT before initiation of empirical antifun-
gal therapy (P = 0.022, HR, 2.03; 95% CI, 1.11-3.71) were signifi-
cantly associated with poor outcomes of empirical antifungal 
therapy with itraconazole.
 The success rate of empirical antifungal therapy in the pa-
tients with positive baseline galactomannan tests was 38.5%. A 
total of 13 baseline fungal infections in 39 patients with positive 
baseline galactomannan tests developed due to Aspergillus and 
5 (38.5%) out of 13 patients were successfully treated. Among 
the patients with positive baseline galactomannan tests, pre-
mature discontinuation of itraconazole therapy because of a 
lack of efficacy occurred in 46.2% (Table 5). The success rate of 
empirical antifungal therapy in the patients with abnormal 
findings on chest X-rays or CT was 46.3%. Meanwhile, 33.9% 
engaged in premature discontinuation of itraconazole therapy 
because of a lack of efficacy.
 
DISCUSSION
We demonstrated that empirical antifungal therapy with itra-
conazole is effective and safe in Korean patients with hemato-
logical malignancies. In this study, we analyzed the success rate 
using the 5 well-known criteria for success of empirical antifun-
gal therapy (13, 15, 16) and reported a 56.5% overall success rate, 
which was comparable to previous trials with other antifungal 
agents (13, 15, 16). Moreover, we also reported that positive ga-
lactomannan tests and abnormal findings on the chest imaging 
Table 4. Overall success rate according to the risk factors of invasive fungal diseases
Risk factors Yes No P value
Age ≥ 60 yr old  60/114 (52.6)  161/277 (58.1) 0.369
Induction/salvage treatment (vs consolidation)  158/291 (54.3)  63/100 (63.0) 0.160
Co-morbidities- cardiovascular disease  30/66 (45.5)  191/325 (58.8) 0.056
Poor ECOG performance status ≥ 2 (vs 0 or 1)  90/174 (51.7)  131/217 (60.4) 0.101
Positive serum galactomannan tests  15/39 (38.5)  106/182 (58.2) 0.033
Abnormal findings on chest X-rays or CT  56/121 (46.3)  165/269 (61.3) 0.006
Definite evidence of fungal infection on CT  10/22 (45.5)  211/368 (57.3) 0.279
Duration of baseline neutropenia
  > 6 days with ANC < 500/µL
  > 10 days with ANC < 500/µL
  > 4 days with ANC < 100/µL
  > 10 days with ANC < 100/µL
 117/204 (57.4)
 65/115 (56.5)
 112/196 (57.1)
 36/61 (59.0)
 104/187 (55.6)
 156/276 (56.5)
 109/195 (55.9)
 185/330 (56.1)
0.760
1.000
0.839
0.779
Duration of baseline neutropenic fever
  ≥ 4 days (vs ≤ 3 days)
  ≥ 5 days (vs ≤ 4 days)
 69/115 (60.0)
 45/71 (63.4)
 152/276 (55.1)
 176/320 (55.0)
0.433
0.234
Antifungal prophylaxis  99/190 (52.1)  122/201 (60.7)  0.102
Data are number of patients with positive results/number of patients tested (%), unless otherwise indicated. ECOG, Eastern Cooperative Oncology Group; CT, computed tomog-
raphy; ANC, absolute neutrophil count.
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tests were risk factors for failure of empirical antifungal therapy 
with itraconazole.
 Although empirical antifungal therapy was usually recom-
mended 3-to-7 days after the onset of neutropenic fever (5, 8, 9), 
early application of empirical antifungal therapy could be pos-
sible in patients with high risk factors for developing IFD. There-
fore, there were no limitations for the time to initiation of em-
pirical antifungal therapy in this study. The median time to start 
empirical antifungal therapy with IV itraconazole was 2 days af-
ter the onset of neutropenic fever. Because the rate of antifungal 
prophylaxis was lower in the “early administration” group, many 
doctors preferred the early use of empirical antifungal agent in 
spite of the short duration of neutropenia. In this study, 291 pa-
tients (74.4%) were considered as the high-risk patients for IFD 
because of residual underlying disease and only about 50% of 
patients received antifungal prophylaxis in spite of general rec-
ommendation of antifungal prophylaxis for high-risk patients 
(25). Furthermore, antifungal agents with weak anti-mold ac-
tivity were used in about 60% of patients. Therefore, we could 
use these data for analyzing risk factors for failure of empirical 
antifungal therapy in spite of relatively early start of empirical 
antifungal therapy.
 Because there was no significant difference in the success 
rate between the “early administration” group and the “routine 
administration” group in this study, we could not consider the 
time to initiation of empirical antifungal therapy as a risk factor 
for failure of empirical antifungal therapy. Although empirical 
antifungal therapy is still recommended because of a high rate 
of mortality and morbidity of IFD (6, 7), a pre-emptive approach 
in which a patient with suspected IFD is treated according to 
the radiologic studies or laboratory markers such as the galac-
tomannan test has recently been emphasized to minimize tox-
icities and costs related to antifungal therapy (17, 26). Therefore, 
we should consider the early application of pre-emptive thera-
py only in the patients with some evidence of IFD.
 The diagnosis of pulmonary IFD is typically difficult because 
invasive diagnostic approaches are not easily available and the 
findings of chest CT are very diverse according to the underly-
ing disease and ANC (27). Therefore, a serum assay for galacto-
mannan has been considered as the most important test for the 
diagnosis of invasive aspergillosis because of its noninvasive 
blood test with high sensitivity and specificity (28). The serum 
galactomannan test can be used for predicting the clinical out-
come in patients with probable or proven invasive aspergillosis 
(29), but little is known about the role of the serum galactoman-
nan test in the setting of empirical antifungal therapy. In this 
study, 39 patients with a positive galactomannan test prior to 
initiation of empirical antifungal therapy were associated with 
a low success rate (38.5%). There were more premature discon-
tinuations of itraconazole therapy in the patients with positive 
baseline galactomannan tests (n = 19, 48.7%) than in the pa-
tients with negative baseline galactomannan tests (23.6%, P =  
0.003). Because these patients had poor outcomes of empirical 
antifungal therapy even after receiving the empirical antifungal 
therapy for a sufficient duration (median 9 days), it seems rea-
sonable to consider the positive baseline galactomannan test as 
a risk factor for failure of empirical antifungal therapy. There-
fore, we may need to consider more potent or combination an-
tifungal therapies in the patients with a positive galactomannan 
test prior to initiation of empirical itraconazole therapy. Because 
the early trend of serum galactomannan levels in the course of 
IFD might be useful in predicting eventual clinical outcomes 
(30, 31), we could consider the early trend of the galactoman-
nan test during the empirical antifungal therapy when we sus-
pected failure of empirical antifungal therapy.
 In this study, the presence of abnormal findings on chest im-
aging tests was also considered an independent risk factor for 
predicting the failure of empirical antifungal therapy. There was 
a significantly higher incidence of abnormal findings on chest 
imaging tests in elderly ( ≥ 60 yr old) patients (54.5% vs 26.0%, 
P = 0.036) and the patients with underlying lung disease (73.9% 
vs 28.3%, P < 0.001). Because abnormal findings on chest imag-
ing tests are usually associated with underlying bacterial infec-
tions, high-resolution CT before initiating empirical antifungal 
therapy is required to find out whether or not the lesions are re-
lated to IFD (4, 5, 11). Although the patients with abnormal find-
ings on chest X-rays or CT also experienced a higher rate of pre-
mature discontinuations of itraconazole therapy (38.0% vs 25.5%, 
Table 5. Comparison of the success rates in the patients with risk factors for failure of empirical antifungal therapy with itraconazole
Risk factors
The patients with positive galactomannan 
tests (n = 39)
The patients with abnormal findings on 
chest X-rays or CT (n = 121)
Overall success rate  15/39 (38.5)  56/121 (46.3)
Successful treatment of baseline fungal infection  5/13 (38.5)  10/20 (50.0)
Absence of breakthrough fungal infection  38/39 (97.4)  119/121 (98.3)
Survival for ≥ 7 days after completion of itraconazole  35/39 (89.7)  110/121 (90.9)
Resolution of fever in setting of neutropenia  18/39 (46.2)  64/121 (52.9)
Itraconazole discontinued prematurely because of toxicity or lack of efficacy 
   Yes
   Lack of efficacy
   Drug toxicity
 19/39 (48.7)
 18/39 (46.2)
 1/39 (2.6)
 46/121 (38.0)
 41/121 (33.9)
 5/121 (4.1)
Data are number of patients with positive results/number of patients tested (%), unless otherwise indicated. CT, computed tomography.
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P < 0.001), these results might be analyzed with caution because 
there were relatively few patients who performed CT (n = 95, 
24.3%) and few patients with definite evidence of fungal infec-
tion on CT (n = 22, 5.6%). Among the 39 patients with positive 
baseline galactomannan tests, 36 patients had normal findings 
on chest X-rays. Therefore, we should perform a high-resolu-
tion CT regardless of the results of chest X-rays if we consider 
the empirical antifungal therapy. 
 There were several limitations of this study. Because this study 
was conducted in the form of an observation study at 22 differ-
ent institutions, we did not standardize the initial antibiotic ther-
apy for neutropenic fever and prophylactic antifungal therapy. 
Two distinct host factors for developing IFD are prolonged neu-
tropenia ( > 10 days) and allogeneic hematopoietic stem cell 
transplantation (HSCT) (4). However, we had relatively few pa-
tients with prolonged baseline neutropenia (29.4%) and few 
patients who received an allogeneic HSCT (4.1%). Because this 
observational study was closer to actual clinical practice and a 
sufficient number of patients for evaluating the characteristics 
of empirical antifungal therapy were enrolled in this study, the 
results from this population could be useful for clinical applica-
tion. Because we did not evaluate the effect of blood concentra-
tion of itraconazole on the success rate in this study, we try to 
make a protocol with therapeutic drug monitoring in a future 
trial.
 In conclusion, this study demonstrated that itraconazole was 
effective and safe in Korean patients with hematological malig-
nancies. Positive galactomannan tests and abnormal findings 
on chest imaging tests at the time of initiation of empirical anti-
fungal therapy are risk factors for failure of empirical antifungal 
therapy with itraconazole. Therefore, we should confirm the re-
sults of serum galactomannan tests and high-resolution CT be-
fore initiation of empirical antifungal therapy to estimate the 
results of empirical antifungal therapy.
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